These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23897275)

  • 1. Responsiveness to change and interpretability of the simplified psoriasis index.
    Chularojanamontri L; Griffiths CEM; Chalmers RJG
    J Invest Dermatol; 2014 Feb; 134(2):351-358. PubMed ID: 23897275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis.
    Chularojanamontri L; Griffiths CE; Chalmers RJ
    J Invest Dermatol; 2013 Aug; 133(8):1956-62. PubMed ID: 23807685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the Simplified Psoriasis Index in Dutch children and adolescents with plaque psoriasis.
    van Geel MJ; Otero ME; de Jong EM; van de Kerkhof PC; Seyger MM
    Br J Dermatol; 2017 Mar; 176(3):771-776. PubMed ID: 27718521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the validity and interpretability of the Simplified Psoriasis Index in Tunisian patients.
    Chabchoub I; Litaiem N; Gara S; Jaber K; Dhaoui MA; Zeglaoui F
    Tunis Med; 2022 Janvier; 100(1):49-55. PubMed ID: 35822332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study.
    Richard MA; Lacour JP; Konstantinou MP; Ruer-Mulard M; Joly P; Aractingi S; Auquier P; Pelvet B; Augustin ML; Mahé E; Chalmers RJG
    J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):677-684. PubMed ID: 32815591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the validity and response distribution of the simplified psoriasis index in patients receiving phototherapy.
    Meah N; Alsharqi A; Azurdia RM; Owens LC; Parslew R; Chularojanamontri L
    Australas J Dermatol; 2018 Feb; 59(1):41-47. PubMed ID: 27730628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [French adaptation of a new score for global assessment of psoriasis severity: The Simplified Psoriasis Index (SPI)].
    Richard MA; Aractingi S; Joly P; Mahé E; Auquier P; Le Guen S; Acquadro C; Boucher F; Chalmers RJG
    Ann Dermatol Venereol; 2019 Dec; 146(12):783-792. PubMed ID: 31623858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Salford Psoriasis Index: an holistic measure of psoriasis severity.
    Kirby B; Fortune DG; Bhushan M; Chalmers RJ; Griffiths CE
    Br J Dermatol; 2000 Apr; 142(4):728-32. PubMed ID: 10792223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a simple measure of psoriasis severity based on a longitudinal study of Chinese patients.
    Cao D; Shen M; Chen X; Xiao Y; Lu W; Luo Y; Zhu W; Kuang Y
    Eur J Dermatol; 2020 Dec; 30(6):674-679. PubMed ID: 33459259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
    Mattei PL; Corey KC; Kimball AB
    J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
    Puig L; Dossenbach M; Berggren L; Ljungberg A; Zachariae C
    Acta Derm Venereol; 2019 Oct; 99(11):971-977. PubMed ID: 31240322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical and psychologic measures are necessary to assess overall psoriasis severity.
    Kirby B; Richards HL; Woo P; Hindle E; Main CJ; Griffiths CE
    J Am Acad Dermatol; 2001 Jul; 45(1):72-6. PubMed ID: 11423838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
    Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
    Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
    Pickard AS; Gooderham M; Hartz S; Nicolay C
    J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.